Evidence map›Paper›PMID 19818023›Full record

ArticleMolecular microbiology2009

Cryptococcus neoformans Site-2 protease is required for virulence and survival in the presence of azole drugs.

Clara M Bien, Yun C Chang, W David Nes, Kyung J Kwon-Chung, Peter J Espenshade

Open access · greenAbstract read
In one paragraph

Article in Molecular microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 62 citations in OpenAlex.

  1. Functional Characterization of a Signal Peptide Peptidase inInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Clara M BienDepartment of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Yun C Chang
W David Nes
Kyung J Kwon-Chung
Peter J Espenshade
Johns Hopkins Medicine · USNational Institutes of Health · USTexas Tech University · US

Funding

Stress Management of Cryptococcal PathogensZIAAI001042 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KWON-CHUNG, KYUNG · 2009 to 2025
$9.6M
Regulation of Cellular Cholesterol HomeostasisR01HL077588 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ESPENSHADE, PETER J. · 2004 to 2022
$7.8M
OXYGEN SENSING AND ADAPTATION TO HOST TISSUE HYPOXIA IN C. NEOFORMANSR21AI072186 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESPENSHADE, PETER J. · 2007 to 2008
$447k
NHLBI NIH HHS HL077588NHLBI NIH HHS R01 HL077588NIAID NIH HHS AI72186NIAID NIH HHS R21 AI072186
6 · The paper itself

Abstract

In the human fungal pathogen Cryptococcus neoformans, the SREBP orthologue Sre1 is important for adaptation and growth in nutrient-limiting host tissues. In this study, we characterize the C. neoformans serotype A Sre1 and its activating protease, Stp1. We demonstrate that Stp1 is a functionally conserved orthologue of the mammalian Site-2 protease and that Stp1 cleaves Sre1 within its predicted first transmembrane segment. Gene expression analysis revealed that Stp1 is required for both Sre1-dependent and Sre1-independent gene transcription, indicating that other substrates of Stp1 may exist. Using gas chromatography, we showed that Sre1 and Stp1 are required for both normoxic and hypoxic ergosterol biosynthesis, and therefore cells lacking SRE1 or STP1 are defective for growth in the presence of low levels of the ergosterol biosynthesis inhibitors, itraconazole and 25-thialanosterol. Importantly, our studies demonstrated fungicidal effects of itraconazole and 25-thialanosterol towards sre1Delta and stp1Delta cells, demonstrating that the Sre1 pathway is required for both growth and survival in the presence of sterol biosynthesis-inhibiting antifungal drugs. Given the need for fungicidal drugs, we propose that inhibitors of Stp1, Sre1, or other regulators of Sre1 function administered in combination with a sterol synthesis inhibitor could prove an effective anticryptococcal therapy.

Indexed as

AnimalsAntifungal AgentsAzolesCryptococcosisCryptococcus neoformansEndopeptidasesFungal ProteinsGene Expression Regulation, FungalGenome, FungalHumansItraconazoleMiceMice, Inbred BALB CMutationPromoter Regions, GeneticProtein KinasesAntifungal AgentsAzolesEndopeptidasesFungal ProteinsItraconazoleProtein KinasesSchizosaccharomyces pombe ProteinsUbiquitin-Protein Ligases

Identifiers

PMID19818023
PMCPMC2917040
OpenAlexW1995127340

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.